Shares of NeuroPace Inc. (NPCE) are down over 60% from their 52-week high of $18.15, recorded in February of this year, and trade around $6.
NeuroPace is a medical device company that markets RNS System, an innovative therapy designed for adults suffering from drug-resistant focal epilepsy.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com